• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy

May 18, 2022 By Sean Whooley

Medtronic Resolute Onyx drug-eluting stent
The Resolute Onyx drug-eluting stent. [Image from Medtronic]
Data presented today at the EuroPCR 2022 event supported the use of the Medtronic (NYSE:MDT) Resolute Onyx drug-eluting stent.

University of Padua Medical School Head of Interventional Cardiology Dr. Giuseppe Tarantini presented late-breaking clinical trial results from the investigator-initiated, Medtronic-funded ROLEX (Revascularization Of LEft Main With Resolute onyX) registry.

ROLEX, the largest real-world, multicenter prospective study, observed the Resolute Onyx drug-eluting stent (DES) in percutaneous coronary interventions (PCI) in the left main artery, according to a news release.

A total of 450 patients were enrolled across 26 centers, receiving a PCI procedure with Resolute Onyx. Intravascular imaging guidance was used in 45% of patients.

One-year data demonstrated strong safety and efficacy, with a low 5.1% rate of target lesion failure (TLF), 2% ischemia-driven target lesion revascularization (ID-TLR) and 1.1% stent thrombosis (ST). In procedures where imaging guidance was employed, those numbers were even lower, with 2% TLF, 1% ID-TLR and 0.5% ST.

The study also demonstrated 98.7% device success in a highly complex patient population, Medtronic said, with 53.4% of patients having acute coronary syndrome, 58.5% having multivessel disease and 30.4% having diabetes.

Resolute Onyx was selected for the study as it is optimized for left main and bifurcation stenting and has 4.5 mm and 5 mm diameter sizes that now expand to 6 mm, plus a single-wire design that enables conformability to achieve optimal strug apposition.

“The data from the ROLEX registry presented today at EuroPCR adds to the unmatched body of evidence supporting Resolute Onyx DES in left main PCI procedures,” Medtronic SVP and President of Coronary and Renal Denervation Jason Weidman said in the release. “We have prioritized investing in product innovation and meaningful evidence to support left main PCI. In addition to ROLEX, the EBC MAIN study showed the benefits of using Resolute Onyx DES to support provisional or two-stent strategies in true left main bifurcations and provided impactful additional data to support physician decision making.”

Strong study results for Resolute Onyx come on the back of last week’s FDA approval for the Onyx Frontier DES.

Onyx Frontier, the latest iteration of Medtronic’s Resolute DES family, was designed to leverage the same stent platform as Resolute with an enhanced delivery system for improving deliverability and increasing acute performance, even in the most challenging of cases.

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents, Vascular Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS